Merck Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MERCK, and what generic alternatives to MERCK drugs are available?
MERCK has ninety-two approved drugs.
There are twenty-six US patents protecting MERCK drugs.
There are seven hundred and thirty-five patent family members on MERCK drugs in sixty-three countries and one hundred and seventy-eight supplementary protection certificates in nineteen countries.
Summary for Merck
International Patents: | 735 |
US Patents: | 26 |
Tradenames: | 77 |
Ingredients: | 70 |
NDAs: | 92 |
Patent Litigation for Merck: | See patent lawsuits for Merck |
PTAB Cases with Merck as patent owner: | See PTAB cases with Merck as patent owner |
Drugs and US Patents for Merck
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Merck | PEPCID PRESERVATIVE FREE | famotidine | INJECTABLE;INJECTION | 019510-004 | Nov 4, 1986 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Merck | HYDROPRES 50 | hydrochlorothiazide; reserpine | TABLET;ORAL | 011958-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Merck | BLOCADREN | timolol maleate | TABLET;ORAL | 018017-004 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Merck | VIOXX | rofecoxib | TABLET;ORAL | 021042-001 | May 20, 1999 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Merck Sharp Dohme | MINTEZOL | thiabendazole | SUSPENSION;ORAL | 016097-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Merck
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Merck Sharp Dohme | TEMODAR | temozolomide | CAPSULE;ORAL | 021029-003 | Aug 11, 1999 | 5,260,291*PED | ⤷ Try a Trial |
Merck Sharp Dohme | DUTREBIS | lamivudine; raltegravir potassium | TABLET;ORAL | 206510-001 | Feb 6, 2015 | 7,169,780*PED | ⤷ Try a Trial |
Merck | CANCIDAS | caspofungin acetate | POWDER;INTRAVENOUS | 021227-002 | Jan 26, 2001 | 5,514,650*PED | ⤷ Try a Trial |
Merck | PRINIVIL | lisinopril | TABLET;ORAL | 019558-003 | Dec 29, 1987 | 4,374,829*PED | ⤷ Try a Trial |
Merck | EMEND | aprepitant | CAPSULE;ORAL | 021549-003 | Jun 30, 2006 | 5,719,147 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for MERCK drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 100 mg/10 mg and 100 mg/40 mg | ➤ Subscribe | 2012-06-19 |
➤ Subscribe | Capsule | 40 mg, 80 mg and 125 mg | ➤ Subscribe | 2008-11-03 |
➤ Subscribe | Tablets | 50 mg/10 mg, 50 mg/20 mg, and 50 mg/40 mg | ➤ Subscribe | 2012-11-06 |
➤ Subscribe | Injection | 150 mg/vial | ➤ Subscribe | 2012-01-25 |
➤ Subscribe | For Injection | 50 mg/vial and 70 mg/vial | ➤ Subscribe | 2009-06-26 |
➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
➤ Subscribe | Capsules | 140 mg and 180 mg | ➤ Subscribe | 2008-03-24 |
➤ Subscribe | Delayed-release Tablets | 100 mg | ➤ Subscribe | 2014-06-16 |
➤ Subscribe | Tablets | 5 mg | ➤ Subscribe | 2006-06-21 |
➤ Subscribe | Tablets | 25 mg, 50 mg and 100 mg | ➤ Subscribe | 2010-10-18 |
➤ Subscribe | Tablets | 100 mg/10 mg and 100 mg/40 mg | ➤ Subscribe | 2012-06-25 |
➤ Subscribe | Injection | 115 mg/vial | ➤ Subscribe | 2012-01-25 |
➤ Subscribe | for Oral Suspension | 125 mg/Kit | ➤ Subscribe | 2016-11-23 |
➤ Subscribe | Oral Solution | 70 mg/75 mL | ➤ Subscribe | 2007-09-07 |
➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
➤ Subscribe | Oral Suspension | 40 mg/mL | ➤ Subscribe | 2011-02-28 |
➤ Subscribe | Injection | 18 mg/mL, 16.7 mL vials | ➤ Subscribe | 2015-11-24 |
➤ Subscribe | Orally Disintegrating Tablets | 2.5 mg and 5 mg | ➤ Subscribe | 2006-06-21 |
International Patents for Merck Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Taiwan | 200716157 | ⤷ Try a Trial |
European Patent Office | 1441735 | ⤷ Try a Trial |
Brazil | PI0213522 | ⤷ Try a Trial |
Canada | 2771879 | ⤷ Try a Trial |
European Patent Office | 2392572 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Merck Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1412357 | PA2007006,C1412357 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: SITAGLIPTINUM; REGISTRATION NO/DATE: EU/1/07/383/001-EU/1/07/383/018 20070321 |
1084705 | SPC/GB14/082 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: SITAGLIPTIN; REGISTERED: UK EU/1/07/383/001-018 20070323; UK EU/1/07/382/001-018 20070323 |
0720599 | 26/2005 | Austria | ⤷ Try a Trial | PRODUCT NAME: EZETIMIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON KOMBINIERT MIT SIMVASTATIN; NAT. REGISTRATION NO/DATE: 1-25673 - 1-25676 20041228; FIRST REGISTRATION: DE 58874.00.00 - 58874.03.00; 58878.00.00 - 20040402 |
1622880 | LUC00070 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: LETERMOVIR; AUTHORISATION NUMBER AND DATE: EU71/17/1245 20180110 |
1622880 | 2018C/025 | Belgium | ⤷ Try a Trial | PRODUCT NAME: LETERMOVIR, DESGEWENST IN DE VORM VAN EEN ZOUT OF SOLVAAT ERVAN OF EEN SOLVAAT VAN EEN ZOUT; AUTHORISATION NUMBER AND DATE: EU/1 /1 7/1245 20170110 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.